http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Antonio Gracco,Laura Siviero,Alessandro Perri,Lorenzo Favero,Edoardo Stellini 대한치과교정학회 2015 대한치과교정학회지 Vol.45 No.6
A 12-year-old girl was referred to our clinic for evaluation of an unaesthetic dental appearance. All permanent teeth were erupted, while the deciduous maxillary right canine was retained. Cone-beam computed tomography revealed a complete transposition of the maxillary left canine and first premolar involving both the crowns and the roots. Initial cephalometric analysis showed a skeletal Class III pattern, with a slight maxillary retrusion and a compensated proclination of the upper incisors. The patient’s teeth were considered to be in the correct position; therefore, we decided to attempt treatment by correcting the transposition and using only orthodontic compensation of the skeletal Class III malocclusion. After 25 months of active orthodontic treatment, the patient had a Class I molar and canine relationship on both sides, with ideal overbite and overjet values. Her profile was improved, her lips were competent, and cephalometric evaluation showed acceptable maxillary and mandibular incisor inclinations. The final panoramic radiograph showed that good root parallelism was achieved. Two-year follow-up intraoral photography showed stable results.
Facial Arterial Depth and Relationship with the Facial Musculature Layer
Lee, Jae-Gi,Yang, Hun-Mu,Choi, You-Jin,Favero, Vittorio,Kim, Yi-Suk,Hu, Kyung-Seok,Kim, Hee-Jin Williams & Wilkins 2015 Plastic and reconstructive surgery Vol.135 No.2
BACKGROUND:: Previous studies have revealed a variation in the origin and distribution patterns of the facial artery. However, the relationship between the facial artery and the facial muscles has not been well described. The purpose of this study was to determine the facial artery depth and relationship with the facial musculature layer, which represents critical information for dermal filler injection and oral and maxillofacial surgery. METHODS:: Fifty-four embalmed adult faces from Korean cadavers (36 male and 18 female cadavers; mean age, 73.3 years) were used in this study. A detailed dissection was performed, with great care being taken to avoid damaging the facial artery underlying the facial skin and muscle. RESULTS:: The facial artery was first categorized according to the patterns of its final arterial branches. The branching pattern was classified simply into three types: type I, nasolabial pattern (51.8 percent); type II, nasolabial pattern with an infraorbital trunk (29.6 percent); and type III, forehead pattern (18.6 percent). Each type was further subdivided according to the facial artery depth and relationship with the facial musculature layer as types Ia (37.0 percent), Ib (14.8 percent), IIa (16.7 percent), IIb (12.9 percent), IIIa (16.7 percent), and IIIb (1.9 percent). CONCLUSION:: This study provides new anatomical insight into the relationships between the facial artery branches and the facial muscles, including providing useful information for clinical applications in the fields of oral and maxillofacial surgery.
de Camargo, Elaine Aparecida,da Silva, Glenda Nicioli,Gobette, Camila Pereira,de Castro Marcondes, Joao Paulo,Salvadori, Daisy Maria Favero Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.10
Tumor response to antineoplastic drugs is not always predictable. This is also true for bladder carcinoma, a highly recurrent neoplasia. Currently, the combination of cisplatin and gemcitabine is well accepted as a standard protocol for treating bladder carcinoma. However, in some cases, this treatment protocol causes harmful side effects. Therefore, we investigated the roles of the genes TP53, RASSF1A (a tumor suppressor gene) and hMLH1 (a gene involved in the mismatch repair pathway) in cell susceptibility to cisplatin/gemcitabine treatment. Two bladder transitional carcinoma cell (TCC) lines, RT4 (wild-type TP53) and 5637 (mutated TP53), were used in this study. First, we evaluated whether the genotoxic potential of cisplatin/gemcitabine was dependent on TP53 status. Then, we evaluated whether the two antineoplastic drugs modulated RASSF1A and hMLH1 expression in the two cell lines. Increased DNA damage was observed in both cell lines after treatment with cisplatin or gemcitabine and with the two drugs simultaneously, as depicted by the comet assay. A lack of RASSF1A expression and hypermethylation of its promoter were observed before and after treatment in both cell lines. On the other hand, hMLH1 downregulation, unrelated to methylation status, was observed in RT4 cells after treatment with cisplatin or with cisplatin and gemcitabine simultaneously (wild-type TP53); in 5637 cells, hMLH1 was upregulated only after treatment with gemcitabine. In conclusion, the three treatment protocols were genotoxic, independent of TP53 status. However, cisplatin was the most effective, causing the highest level of DNA damage in both wild-type and mutated TP53 cells. Gemcitabine was the least genotoxic agent in both cell lines. Furthermore, no relationship was observed between the amount of DNA damage and the level of hMLH1 and RASSF1A expression. Therefore, other alternative pathways might be involved in cisplatin and gemcitabine genotoxicity in these two bladder cancer cell lines.